Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase

Experimental Biology and Medicine

Volumn 238, Issue 9, 2013, Pages 1082-1094

  Xu, Xuefeng ^a,b   Wan, Xuan ^a,b   Geng, Jing ^a,b   Li, Fei ^a,b   Yang, Ting ^a,b   Dai, Huaping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Respiratory Medicine   (China)

Author keywords

Connective tissue growth factor; epithelial cell; idiopathic pulmonary fibrosis; migration; rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (1, 3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL] BENZAMIDE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKERATIN 18; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN ISOLATION; RADIOIMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL CELL; IDIOPATHIC PULMONARY FIBROSIS; MIGRATION; RAPAMYCIN;

CELL LINE, TRANSFORMED; CELL MOVEMENT; CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL CELLS; HUMANS; LUNG; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84884233813     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213498976     Document Type: Article

References (43)

1. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).Am J Respir Crit Care Med. 2000;161 (2 Pt 1): 646-64.
2. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.Am J Respir Crit Care Med. 2002;165:277-304.
3. Fernandez Perez ER,Daniels CE,Schroeder DR,St Sauver J,Hartman TE,Bartholmai BJ, et al.Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.Chest. 2010;137:129-37.
4. King TE,Pardo A,Selman M.Idiopathic pulmonary fibrosis.Lancet. 2011;378:1949-61.
5. Coward WR,Saini G,Jenkins G.The pathogenesis of idiopathic pulmonary fibrosis.Ther Adv Respir Dis. 2010;4:367-88.
6. Kottmann RM,Hogan CM,Phipps RP,Sime PJ.Determinants of initiation and progression of idiopathic pulmonary fibrosis.Respirology. 2009;14:917-33.
7. Hardie WD,Hagood JS,Dave V,Perl AK,Whitsett JA,Korfhagen TR, et al.Signaling pathways in the epithelial origins of pulmonary fibrosis.Cell Cycle. 2010;9:2769-76.
8. Crosby LM,Waters CM.Epithelial repair mechanisms in the lung.Am J Physiol Lung Cell Mol Physiol. 2010;298:L715-31.
9. Lee CG,Cho SJ,Kang MJ,Chapoval SP,Lee PJ,Noble PW, et al.Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis.J Exp Med. 2004;200:377-89.
10. Drakopanagiotakis F,Xifteri A,Polychronopoulos V,Bouros D.Apoptosis in lung injury and fibrosis.Eur Respir J. 2008;32:1631-8.
11. Vezina C,Kudelski A,Sehgal SN.Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.J Antibiot (Tokyo). 1975;28:721-6.
12. Wullschleger S,Loewith R,Hall MN.TOR signaling in growth and metabolism.Cell. 2006;124:471-84.
13. Dancey J.mTOR signaling and drug development in cancer.Nat Rev Clin Oncol. 2010;7:209-19.
14. Bridle KR,Popa C,Morgan ML,Sobbe AL,Clouston AD,Fletcher LM, et al.Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways.Liver Transpl. 2009;15:1315-24.
15. Korfhagen TR,Le Cras TD,Davidson CR,Schmidt SM,Ikegami M,Whitsett JA, et al.Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.Am J Respir Cell Mol Biol. 2009;41:562-72.
16. Simler NR,Howell DC,Marshall RP,Goldsack NR,Hasleton PS,Laurent GJ, et al.The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats.Eur Respir J. 2002;19:1124-7.
17. de Winter P,Leoni P,Abraham D.Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein.Growth Factors. 2008;26:80-91.
18. Schmittgen TD,Livak KJ.Analyzing real-time PCR data by the comparative C(T) method.Nat Protoc. 2008;3:1101-8.
19. Pilquil C,Dewald J,Cherney A,Gorshkova I,Tigyi G,English D, et al.Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation.J Biol Chem. 2006;281:38418-29.
20. Osman B,Doller A,Akool el S,Holdener M,Hintermann E,Pfeilschifter J, et al.Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.Cell Signal. 2009;21:1806-17.
21. Carracedo A,Ma L,Teruya-Feldstein J,Rojo F,Salmena L,Alimonti A, et al.Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.J Clin Invest. 2008;118:3065-74.
22. Sehgal SN.Sirolimus: its discovery, biological properties, and mechanism of action.Transplant Proc. 2003;35:7S-14S.
23. Martel RR,Klicius J,Galet S.Inhibition of the immune response by rapamycin, a new antifungal antibiotic.Can J Physiol Pharmacol. 1977;55:48-51.
24. Abraham RT,Gibbons JJ.The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Clin Cancer Res. 2007;13:3109-14.
25. Hwang M,Perez CA,Moretti L,Lu B.The mTOR signaling network: insights from its role during embryonic development.Curr Med Chem. 2008;15:1192-208.
26. Brigstock DR.Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals.J Cell Commun Signal. 2010;4:1-4.
27. Leask A,Holmes A,Abraham DJ.Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis.Curr Rheumatol Rep. 2002;4:136-42.
28. Sonnylal S,Shi-Wen X,Leoni P,Naff K,Van Pelt CS,Nakamura H, et al.Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.Arthritis Rheum. 2010;62:1523-32.
29. Kodama T,Takehara T,Hikita H,Shimizu S,Shigekawa M,Tsunematsu H, et al.Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.J Clin Invest. 2011;121:3343-56.
30. Dendooven A,Gerritsen KG,Nguyen TQ,Kok RJ,Goldschmeding R.Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis.Biomarkers. 2011;16:289-301.
31. O'Connell S,Slattery C,Ryan MP,McMorrow T.Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells.J Transplant. 2012;2012:980910-980910.
32. Shihab FS,Bennett WM,Yi H,Andoh TF.Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.Am J Nephrol. 2006;26:400-7.
33. Liu M,Zhang W,Gu M,Yin C,Zhang WY,Lv Q, et al.Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy.Transplant Proc. 2007;39:1410-5.
34. Vivanco I,Sawyers CL.The phosphatidylinositol 3-kinase AKT pathway in human cancer.Nat Rev Cancer. 2002;2:489-501.
35. Engelman JA,Luo J,Cantley LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.Nat Rev Genet. 2006;7:606-19.
36. Stephens L,Anderson K,Stokoe D,Erdjument-Bromage H,Painter GF,Holmes AB, et al.Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.Science. 1998;279:710-4.
37. Georgescu MM.PTEN tumor suppressor network in PI3K-Akt pathway control.Genes Cancer. 2010;1:1170-7.
38. Fan QW,Knight ZA,Goldenberg DD,Yu W,Mostov KE,Stokoe D, et al.A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.Cancer Cell. 2006;9:341-9.
39. Sun SY,Rosenberg LM,Wang X,Zhou Z,Yue P,Fu H, et al.Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.Cancer Res. 2005;65:7052-8.
40. O'Reilly KE,Rojo F,She QB,Solit D,Mills GB,Smith D, et al.mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.Cancer Res. 2006;66:1500-8.
41. Roberts PJ,Usary JE,Darr DB,Dillon PM,Pfefferle AD,Whittle MC, et al.Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.Clin Cancer Res. 2012;18:5290-303.
42. Lorenzen JM,Schonenberger E,Hafer C,Hoeper M,Kielstein JT.Failed rescue therapy with rapamycin after paraquat intoxication.Clin Toxicol (Phila). 2010;48:84-6.
43. Madala SK,Maxfield MD,Davidson CR,Schmidt SM,Garry D,Ikegami M, et al.Rapamycin regulates bleomycin-induced lung damage in SP-C-deficient mice.Pulm Med. 2011;2011:653524-653524.